Consistent with these findings, our data analytics confirmed that MerTK is highly expressed in activated plasma B cells responding to tumor environment but is lowly expressed in alpha-beta T cells, CD4+ central and effector memory T cells, and CD4+CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.